Emcure Pharmaceuticals has informed that pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’), read with Schedule III of aforesaid regulation, the Board of Directors of the Company at its meeting held today, Saturday, June 21, 2025, has transacted and approved the following businesses: Approval for acquisition of Equity Shares of Zuventus Healthcare, Subsidiary of the Company; Approval of the requests received from certain members of Promoter and Promoter Group for seeking re-classification from ‘Promoter and Promoter Group’ category to ‘Public’ category of the Company; Incorporation of a wholly-owned Subsidiary by the name ‘Emcure Wellness Private Limited’ in Pune, Maharashtra, India.
The above information is a part of company’s filings submitted to BSE.
